Jiyun Lee
성균관대학교 의과대학 · 의학
이 교수의 연구실은 고도로 전문화된 타겟 치료 및 면역요법을 중심으로 한 비소세포성 폐암, 유방암 등 흔한 암 종양의 분자적 기전과 치료 내성 메커니즘을 규명하고 있습니다. 특히 HER2, EGFR, ALK/ROS1, RET, KRAS 등 암 관련 유전자 변이를 가진 환자군을 대상으로 한 표적치료제의 임상적 유효성과 내성 원인을 분석하며, 뇌전이 등 치료 난이도가 높은 병변에 대비한 혁신적 치료 전략 개발에 주력하고 있습니다. 또한 다양한 인종 간 치료 반응의 유사성과 차이를 분석함으로써 개인화된 암 치료의 정착을 위한 근거를 마련하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Trastuzumab deruxtecan (T-DXd, DS-8201), an anti-HER2 antibody-drug conjugate, has shown significant clinical benefits in HER2+ metastatic breast cancer patients. In the phase 2 DESTINY-Breast01 trial, T-DXd demonstrated an objective response of 60.9% and median progression-free survival of 16.4 months, laying the foundation for accelerated approval in HER2+ metastatic breast cancer patients who have received two or more prior anti-HER2-based regimens in the metastatic setting. Moreover, T-DXd e
Resistance acquired after third-generation EGFR TKIs is associated with diverse pathways; however, treatment with osimertinib is primarily associated with a loss of EGFR T790M and the subsequent emergence of EGFR-independent resistance mechanisms.
Immunotherapy, especially immune checkpoint inhibitors, has revolutionized the treatment of non-small cell lung cancer. However, data on ethnic differences in response to these treatments are still lacking. We reviewed the currently available clinical data on immune checkpoint inhibitors and analyzed the ethnic difference in terms of treatment efficacies and side effects. Despite different epidemiology, genetic susceptibility and molecular profiles, Asian lung cancer patients demonstrated compar
Given the likelihood of RET-rearranged NSCLC progressing to intracranial metastases and the absence of apparent clinical benefit of currently available targeted or immunotherapeutic agents, development of novel treatment with higher selectivity and better penetration of the blood-brain barrier remains a priority.
This study is the first to report that lorlatinib is an important novel therapeutic option for Asian patients who have advanced NSCLC harboring ALK/ROS1 mutations whose disease progressed during treatment with first- and second-generation TKIs.
Whereas treatment outcomes with conventional anticancer therapy are reasonable and immunotherapy looks promising, the unmet need remains high for patients with <i>KRAS</i>-mutated NSCLC in Asia, underscoring the need for novel therapeutic approaches.
This study includes the largest set of integrated genomic data analyzing Asian patients with melanoma treated with immunotherapy. BRAF <sup>V600</sup> and KIT mutational statuses were not associated with response or survival, and high NLR was a strong predictor of poor response to and survival with anti-PD-1 therapy.
